Stock Information

 

In this section you will find detailed information regarding the Evotec SE share, ranging from basic share data over stock charts, shareholder structure, our financial analysts, our auditors to our dividend policy.  

 

Basic Share Data

Listing on Frankfurt Stock Exchange (XETRA)
Listing NASDAQ, New York
Security identification numbers
 
Ordinary bearer shares
ISIN: DE0005664809
 

American Depositary Shares (“ADSs”)
ISIN:
US30050E1055

Ticker symbol

Frankfurt Stock Exchange: EVT


NASDAQ: EVO

Bloomberg Xetra: EVT GY Equity

Reuters Xetra: EVTG.DE

Stock exchange

Frankfurt Stock Exchange
NASDAQ New York
Segment
Prime Standard
Global Select Market
Index
MDAX, TecDAX, Prime All Share, LTecDAX, Technology All Share, CDAX
n/a
Designated Sponsor
ODDO SEYDLER BANK AG
Paying agent
Deutsche Bank AG, Frankfurt am Main
J.P. Morgan
Number of shares issued
176,952,653 ordinary bearer shares
20,000,000 ADSs (10,000,000 ordinary shares)

Nominal capital

€ 176,952,653
€ 176,952,653
Security identification numbers
 
Listing on Frankfurt Stock Exchange (XETRA)
Ordinary bearer shares
ISIN: DE0005664809
 
Listing NASDAQ, New York

American Depositary Shares (“ADSs”)
ISIN:
US30050E1055

Ticker symbol

Listing on Frankfurt Stock Exchange (XETRA)

Frankfurt Stock Exchange: EVT


Listing NASDAQ, New York

NASDAQ: EVO

Bloomberg Xetra: EVT GY Equity

Reuters Xetra: EVTG.DE

Stock exchange

Listing on Frankfurt Stock Exchange (XETRA) Frankfurt Stock Exchange
Listing NASDAQ, New York NASDAQ New York
Segment
Listing on Frankfurt Stock Exchange (XETRA) Prime Standard
Listing NASDAQ, New York Global Select Market
Index
Listing on Frankfurt Stock Exchange (XETRA) MDAX, TecDAX, Prime All Share, LTecDAX, Technology All Share, CDAX
Listing NASDAQ, New York n/a
Designated Sponsor
Listing on Frankfurt Stock Exchange (XETRA) ODDO SEYDLER BANK AG
Listing NASDAQ, New York
Paying agent
Listing on Frankfurt Stock Exchange (XETRA) Deutsche Bank AG, Frankfurt am Main
Listing NASDAQ, New York J.P. Morgan
Number of shares issued
Listing on Frankfurt Stock Exchange (XETRA) 176,952,653 ordinary bearer shares
Listing NASDAQ, New York 20,000,000 ADSs (10,000,000 ordinary shares)

Nominal capital

Listing on Frankfurt Stock Exchange (XETRA) € 176,952,653
Listing NASDAQ, New York € 176,952,653

Listing on NASDAQ

Since November 2021 Evotec SE is listed on NASDAQ (Ticker Symbol: EVO).

Please find all further information regarding the NASDAQ listing as well as al published filings of Evotec SE under the following link:

Link to SEC/EDGAR

Stock Price & Chart

Shareholder structure

On 31 January 2022, the number of total voting rights amounts to 176,952,653.

Under the German Securities Trading Act (Wertpapierhandelsgesetz, WpHG), shareholders of a listed German company are required to notify the Company and the German Federal Financial Supervisory Authority (BaFin) of any change to the voting interest in Evotec SE whenever it reaches, exceeds or falls below specified thresholds (3%, 5%, 10%, 15%, 20%, 25%, 30%, 50% or 75% of the voting rights). Evotec’s voting rights announcements can be found at dgap.de.

Three shareholders, Novo Holdings A/S, T. Rowe Price Group Inc. and Mubadala Investment Company, currently hold more than 5% of the shares of Evotec SE. The free float according to the definition of the Frankfurt Stock Exchange is approx. 68% according to our estimates (Evotec: 01|2022).

 

Shareholder structure (in %)*

* Rounding differences may occur.

Analysts

Overview of analysts covering the Evotec share

Bank of America Derik de Bruin

 

BofA Securities

NYI-100-16-03

One Bryant Park

New York, NY  10036

 

Berenberg Igor Kim

Berenberg

Bockenheimer Landstraße 25

60325 Frankfurt

 

Citigroup Inc. Peter Verdult
One Court Square, 45th Floor, Long Island City, New York 11120, USA
Cowen Steven Mah

 Two International Place, Boston, MA 02110

Deutsche Bank Falko Friedrichs
Große Gallusstraße 10-14, 60311 Frankfurt am Main
EQUI.TS GmbH Thomas Schiessle
Am Schieferstein 1, 60435 Franfkurt am Main
FMR Frankfurt Main Research Dr Mohamad Vaseghi
Kleiner Hirschgraben 10-12, 60311 Frankfurt, Germany
goetzpartners securities Limited Dr Chris Redhead
goetzpartners securities Limited, The Stanley Building, 7 Pancras Square, London N1C 4AG, United Kingdom
Intron Health Naresh Chouhan
New Street Research LLP, 11 Austin Friars, London, EC2N 2HG
Jefferies Peter Welford

Jefferies, 520 Madison Avenue, New York, NY 10022

Kempen & Co. N.V. Sebastiaan van der Schoot

Beethovenstraat 300, 1077 WZ Amsterdam, The Netherlands

Morgan Stanley James Quigley

Morgan Stanley & Co. LLC, 1585 Broadway Avenue, New York, NY 10036

 

Stifel Europe Bank Dr Marcus Wieprecht
Kennedyallee 76, 60596 Frankfurt am Main, Germany
Royal Bank of Canada (RBC) Charles Weston
Royal Bank of Canada Europe Ltd., Thames Court, One Queenhithe, London EC4V 3DQ, UK
Rx Securities Dr Samir Devani
1 Fore Street, Moorgate, Third Floor, London EC2Y 9DT, United Kingdom
Warburg Research Dr Christian Ehmann
Ferdinandstraße 75, 20095 Hamburg, Germany

Latest analyst recommendations

Below you will find the latest analyst recommendations.

Analyst
Recommendation
Target price
Date of latest
Research Report
Citigroup Inc.
NEUTRAL
30.00 EUR
13 May 2022
Cowen
OUTPERFORM
50.00 EUR
29 November 2021
Deutsche Bank
BUY
30.00 EUR
30 May 2022
Frankfurt Main Research (FMR)
BUY
36.50 EUR
3 February 2021
Jefferies
BUY
45.00 EUR
11 May 2022
Kempen & Co. N.V.
BUY
30.00 EUR
11 May 2022
Morgan Stanley
OVERWEIGHT
22.00 EUR
14 June 2022
Stifel Europe Bank
BUY
35.00 EUR
17 March 2022
Royal Bank of Canada (RBC)
OUTPERFORM
43.00 EUR
17 May 2022
Rx Securities
BUY
44.00 EUR
17 May 2022
Warburg Research
BUY
38.00 EUR
12 May 2022
Average target price
36.68 EUR
Analyst Citigroup Inc.
Recommendation NEUTRAL
Target price 30.00 EUR
Date of latest
Research Report
13 May 2022
Analyst Cowen
Recommendation OUTPERFORM
Target price 50.00 EUR
Date of latest
Research Report
29 November 2021
Analyst Deutsche Bank
Recommendation BUY
Target price 30.00 EUR
Date of latest
Research Report
30 May 2022
Analyst Frankfurt Main Research (FMR)
Recommendation BUY
Target price 36.50 EUR
Date of latest
Research Report
3 February 2021
Analyst Jefferies
Recommendation BUY
Target price 45.00 EUR
Date of latest
Research Report
11 May 2022
Analyst Kempen & Co. N.V.
Recommendation BUY
Target price 30.00 EUR
Date of latest
Research Report
11 May 2022
Analyst Morgan Stanley
Recommendation OVERWEIGHT
Target price 22.00 EUR
Date of latest
Research Report
14 June 2022
Analyst Stifel Europe Bank
Recommendation BUY
Target price 35.00 EUR
Date of latest
Research Report
17 March 2022
Analyst Royal Bank of Canada (RBC)
Recommendation OUTPERFORM
Target price 43.00 EUR
Date of latest
Research Report
17 May 2022
Analyst Rx Securities
Recommendation BUY
Target price 44.00 EUR
Date of latest
Research Report
17 May 2022
Analyst Warburg Research
Recommendation BUY
Target price 38.00 EUR
Date of latest
Research Report
12 May 2022
Analyst Average target price
Recommendation
Target price 36.68 EUR
Date of latest
Research Report

Latest Analyst Consensus (Q1 2022)

 

Important Notice:

Evotec is covered and evaluated by the analysts mentioned above. Please note that any opinions, estimates or forecasts regarding Evotec's performance made by these analysts are theirs alone and do not represent opinions, estimates or forecasts of Evotec or its management. The above reference to the analysts does not imply that Evotec endorses their opinions. Evotec is under no obligation to update or supplement the information provided above and does not guarantee the accuracy or completeness of this list.

Copies of the reports from the analysts listed above can be obtained directly from the analysts or their employers. Due to legal requirements, Evotec is not allowed to publish the analyst reports. 

 

Evotec's Dividend Policy

The payment of dividends depends on Evotec’s financial situation and liquidity requirements, general market conditions, and statutory, tax and regulatory requirements. 

Evotec has never paid or declared any cash dividends on its ordinary shares, and does not anticipate paying any cash dividends on its ordinary shares in the foreseeable future. Evotec intends to retain all available funds and any future earnings and reinvest them in the company’s further growth strategy to better leverage longterm growth and sustainability.

Under German law, Evotec may pay dividends only from the distributable profit (Bilanzgewinn) reflected in its unconsolidated financial statements (as opposed to the consolidated financial statements for Evotec and its subsidiaries) prepared in accordance with the principles set forth in the German Commercial Code (Handelsgesetzbuch) and adopted by the Evotec Management Board (Vorstand) and the Supervisory Board (Aufsichtsrat), or, as the case may be, by the shareholders of Evotec in a general shareholders’ meeting. In addition, under German law Evotec may not pay dividends before annual profits exceed the losses carried forward. 

All of the shares represented by the ADSs offered in USA generally have the same dividend rights as all of Evotec's other outstanding shares.

 

TOP